Prescribing trends for dabigatran etexilate in primary care. [PDF]
At the time of the analysis, dabigatran etexilate was licensed, in Ireland, for thromboprophylaxis in adults after elective total hip- and total knee-replacement only.
McCullagh, L, Barry, M
core
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation [PDF]
Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant, versus warfarin and other alternatives for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation (AF).
Pan, Feng +6 more
core +1 more source
Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)
Objective: The D-SPIRIT registry is designed to investigate the safety and efficacy of dabigatran etexilate in patients with nonvalvular atrial fibrillation (NVAF) and to collect data on outcomes in clinical practice.
Uğur Önsel Türk +14 more
doaj +1 more source
Stability of Dabigatran Etexilate in Manufacturer’s Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack [PDF]
Background: Dabigatran, a direct thrombin inhibitor, is indicated for the prevention and treatment of venous thromboembolism and for stroke prophylaxis in atrial fibrillation.
Semchuk, William +4 more
core +1 more source
Dabigatran etexilate is a relatively new anticoagulant from the class of direct thrombin inhibitors which is administered orally and does not require routine blood work monitoring.
Allen R. Wolfe, MD, MPH +5 more
doaj +1 more source
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo +5 more
wiley +1 more source
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source
Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation [PDF]
dabigatran etexilate, warfarin, oral anticoagulation, atrial fibrillation, efficacy, safety.Introduction Oral anticoagulation is the mainstay for stroke and thromboembolic events prevention in patients with atrial fibrillation (AF).
Dzeshka, M. S., Lip, G. Y.
core
The effects of dabigatran etexilate on fracture healing in rats An experimental study
Yenilmez, Engin/0000-0002-0755-4394; Kerimoglu, Gokcen/0000-0002-4349-7796Background: Deep vein thrombosis leading to pulmonary embolism is one of the major complication after fracture. After a fracture occurs, the coagulation cascade activates thrombin,
Onay, Atılgan +8 more
core +1 more source
Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation : the IDEA Study [PDF]
BACKGROUND AND OBJECTIVES: Warfarin-related nephropathy is an unexplained acute kidney injury, and may occur in patients with supratherapeutic INR, in the absence of overt bleeding.
Polo Friz, Hernan +8 more
core +1 more source

